This statistic displays the number of adults with a mood disorder in the United States in the period 2008-2012, by age group. During this time, some *** million individuals between the ages of 26 and 49 years had major depressive disorder. Mood depressive disorders describe a serious change in mood. Depression can be common among individuals with mental illnesses.

Number and percentage of persons having been diagnosed with a mood disorder, by age group and sex.

In 2022, over 1.4 million people were treated for neurotic and mood disorders in France. That year, with roughly 390,000 patients, the highest prevalence for such disorders was found within the age group of 35 to 54 years.

In the United States, the prevalence of mental illness in the past year is more common among females than males and more common among the young than the old. As of 2023, some 26.4 percent of females reported some type of mental illness in the past year, compared to 19 percent of males. Common forms of mental illness include depression, anxiety disorders, and mood disorders. Depression Depression is one of the most common mental illnesses in the United States. Depression is defined by prolonged feelings of sadness, hopelessness, and despair leading to a loss of interest in activities once enjoyed, a loss of energy, trouble sleeping, and thoughts of death or suicide. It is estimated that around five percent of the U.S. population suffers from depression. Depression is more common among women with around six percent of women suffering from depression compared to four percent of men. Mental illness and substance abuse Data has shown that those who suffer from mental illness are more likely to suffer from substance abuse than those without mental illness. Those with mental illness are more likely to use illicit drugs such as heroin and cocaine, and to abuse prescription drugs than those without mental illness. As of 2023, around 7.9 percent of adults in the United States suffered from co-occuring mental illness and substance use disorder.

In 2017, around 19 percent of Aboriginal individuals in Canada aged 15 to 24 years reported having a mood disorder. This statistic illustrates the percentage of Aboriginal individuals in Canada with a self-reported long-term mood disorder in 2017, by age.

Introduction

Depression Statistics: Depression is a very common mental disorder. It involves a persistent feeling of sadness or reduced interest in activities over an extended period. Depression is different from normal mood fluctuations and everyday emotional responses. It impacts all aspects of life, including relationships with family, friends, and the community. Anyone, regardless of age, can experience depression. Individuals who have experienced trauma, significant losses, or other stressful events are more likely to develop depression.

Women are more likely to experience depression than men. Identifying depression in individuals can be challenging, as it is not always predictable. In this article, we will delve into Depression Statistics to provide more insight.

Notes: Significant findings are in bold.

Across all but one of the surveyed age groups, females living in Australia were more likely than males to have a 12-month affective disorder in the 2021 financial year. Males aged 55-64 were the exception, with approximately 6.3 percent of males in that age group compared to 4.9 percent of females.

Comparison of demographics and new psychiatric disorders between people with COVID-19 and those without COVID-19 in 2020.

A survey from 2023-2024 of college students in the United States found that the most common mental disorders that college students have been diagnosed with are anxiety disorders and depression or other mood disorders. Around ** percent of the college students surveyed at that time reported they had been diagnosed with an anxiety disorder at some point in their lifetime. Depression among college students Although college can be an exciting time, it can also be stressful and difficult. College students are often faced with new challenges related to living alone, their academic performance, the financial burden of attending college, and new social interactions. Therefore, anxiety and symptoms of depression are not uncommon among college students. In fact, it is estimated that up to ** percent of college students in the U.S. had symptoms of depression in 2023. Thankfully, depressive symptoms can usually be successfully treated through therapy, medication, lifestyle changes, or a combination of these. However, if left untreated depression can lead to thoughts of suicide or self-harm. A survey from 2023, found that up to ** percent of U.S. college students had thoughts of suicide in the past year. Mental health help on campus Many colleges in the United States have recognized the stress and anxiety that students can experience and now offer mental health resources on campus. However, barriers to access mental health services still exist. For example, as of 2024, around ** percent of surveyed college students in the U.S. indicated that they were not sure where on their campus to seek professional help for their mental or emotional health. Furthermore, around ** percent of students stated that they received fewer mental or emotional health services than they otherwise would have due to not having enough time for such services, while ** percent said they received fewer services due to financial reasons.

NA = information was not documented in medical file; Short Duration = written as “short duration” in the medical file, no time/quantifiable duration recorded; TBI severity reported according to Mayo Classification System [29]; SP = symptomatic possible TBI; MP = mild probable TBI; MSD = Moderate-severe definite TBI. *Previous skull fracture as infant (

The global antimania drug market is a significant and growing sector within the pharmaceutical industry, projected to experience substantial growth over the forecast period (2025-2033). While precise market size figures for 2025 were not provided, a reasonable estimate, considering the typical size of specialty pharmaceutical markets and a moderate CAGR (let's assume 5% for illustrative purposes), could place the 2025 market value at approximately $5 billion. This growth is fueled by several key drivers, including the increasing prevalence of bipolar disorder across various age groups (children, teenagers, middle-aged adults, and the elderly), rising awareness and improved diagnosis rates, and the continued development of novel treatment options with improved efficacy and safety profiles. Market segmentation reveals significant demand across different age demographics, with potential for future growth driven by targeted therapies tailored to specific age-related needs. The availability of various drug types, such as Lithium Carbonate and others (potentially including newer mood stabilizers and antipsychotics), contributes to market diversification. Geographic variations in market size and growth are anticipated, reflecting disparities in healthcare infrastructure, access to medications, and prevalence of bipolar disorder across different regions. Market restraints include the potential for adverse effects associated with some antimania drugs, necessitating careful monitoring and patient management. High treatment costs and limited insurance coverage in some regions can also hinder access to these crucial medications. However, ongoing research and development efforts aimed at improving the safety and efficacy of antimania drugs, alongside advancements in personalized medicine, are expected to mitigate these challenges. Furthermore, the competitive landscape, involving major pharmaceutical players such as Eli Lilly and Company, AstraZeneca, Pfizer, Xian Janssen Pharmaceutical Ltd., Otsuka Pharmaceutical, and Allergan, fosters innovation and ensures a steady supply of these essential medications. Continued investment in research and patient education are essential to realizing the full potential of this market and improving the lives of individuals affected by bipolar disorder.

Leveraging technology to probe mechanisms of psychopathology: A proof of concept study of inhibitory control

A comprehensive dataset for the data included in the manuscript entitled “Leveraging technology to probe mechanisms of psychopathology: A proof of concept study of inhibitory control”. This dataset contains demographic variables, parent-reported and child-reported clinical symptoms, behavior from four canonical cognitive function neuropsychological tests, behavioral responses from a novel mobile application assessing inhibitory control, along with structural and functional magnetic resonance imaging (MRI) data.

Participant Eligibility

Participants included youth ages 8 – 18 years. To be eligible for the study, participants needed to be able to read, speak, and understand English and meet diagnostic criteria for either a primary diagnosis of an anxiety disorder (generalized, social, and/or separation anxiety disorder), disruptive mood dysregulation disorder (DMDD), or ADHD. In addition, youth were included with clinically-significant irritability not meeting the threshold for DMDD (ie. significant irritability but only in one setting) and youth with no psychiatric diagnosis (as assessed by a clinical using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (KSADS-PL). Participants were excluded for: IQ<70; diagnosis of autism spectrum disorder, past and/or current posttraumatic stress disorder, schizophrenia, or major depression; substance use within the past three months; and neurological disorder. Parents and youth completed written informed consent and assent, respectively. Families received monetary compensation.

Of the 200 participants included in analyses, only 160 consented to share their data publicly and are included in this dataset.

Clinical Measures

All symptoms were assessed by parent- and child-report questionnaires. Anxiety symptoms were assessed using the Screen for Child Anxiety Related Emotional Disorders (SCARED). Five subscale scores (Generalized Anxiety, Panic, Social Anxiety, Separation Anxiety, School Anxiety) were calculated. Irritability symptoms were assessed using the Affective Reactivity Index (ARI). Item-level responses to the six items included in the total score were extracted. ADHD symptoms were assessed using the Conners Comprehensive Behavior Rating Scale (CBRS). Six items from the DSM-IV ADHD Total raw score were selected (three inattention and three hyperactivity/impulsivity items with the highest factor loadings on an ADHD latent variable). Depressive symptoms were assessed using the Mood and Feelings Questionnaire (MFQ).

Eligible participants completed a novel mobile-application for the assessment of inhibitory control. Behavior was operationalized in the following manner: percentage of targets correctly swiped as “hit rate”, percentage of targets incorrectly not-swiped as “miss rate,” percentage of stars incorrectly swiped “false alarm rate,” and percentage of stars correctly not-swiped as “correct rejection rate”. For each participant, d-prime was calculated as the difference between the standardized percentage of correct hits and the standardized percentage of false alarms.

A subset of participants completed also four canonical cognitive function neuropsychological tests: Anti-Saccade Task, AX Continuous Performance Task (AX-CPT), Flanker Task, & Stop Signal Delay Task. A measure of inhibitory control was extracted from each of the four tasks. For Anti-Saccade, we calculated the percentage of correct anti-saccade trials across all anti-saccade trials. For AX-CPT, we calculated d’ context. For Flanker task, we calculated the reaction time difference between correct responses to incongruent vs. congruent trials. And for the Stop Signal Delay Task we calculated stop-signal reaction time.

Biological and Physiological measures

No biological or physiological measures were included in any analyses.

Imaging data

Participants were given the option to additionally participate in optional magnetic resonance imaging (MRI). We measured blood-oxygen-level-dependent (BOLD) changes during the Eriksen Flanker Task with 170 whole brain T*2 weighted echo-planer images acquired using a 3T MR750 General Electric Scanner and a 32-channel head coil (TR=2000ms, TE=25, flip angle=60, field of view=96x96, slices=42/axial/3mm ). For each participant, we also collected structural images using a magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence (TR=7.66, TE=3.42, flip angle=7, field of view=256x256, slices=176/sagittal/1mm). Seed coordinates for ROIs were selected using a Neurosynth term-based meta-analysis with the term “cognitive control” (anterior cingulate [ACC], supplementary motor area [SMA], and the bilateral inferior frontal gyrus [IFG]). 𝑧-value maps (uniformity test for “cognitive control”), FDR-corrected to 0.01, were further thresholded to a 𝑧-value of 10. For each participant, percent BOLD signal change was extract in each ROI for each task condition (congruent vs incongruent trials).

This dataset is about: Apectodinium, age and percentage of endemic and bipolar dinoflagellate cysts of ODP Hole 189-1171D. Please consult parent dataset @ https://doi.org/10.1594/PANGAEA.816368 for more information.

The global aripiprazole market size was valued at USD 6.03 billion in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 5.31% during the forecast period, reaching a value of USD 8.60 billion by 2033. The market growth is attributed to the increasing prevalence of schizophrenia, bipolar disorder, and other mental health conditions, as well as the rising awareness of these conditions. Additionally, the development of novel formulations and the expansion of the generic market are expected to contribute to market growth. The market for aripiprazole is segmented by indication, dosage form, distribution channel, and patient age group. The schizophrenia segment is expected to hold the largest share of the market throughout the forecast period. The oral tablet segment is expected to dominate the market due to the convenience and ease of administration. The hospital pharmacy segment is expected to account for the largest share of the distribution channel due to the high volume of prescriptions filled in this setting. The adult segment is expected to hold the largest share of the market due to the higher prevalence of mental health conditions in this age group. The global Aripiprazole market is projected to reach $10.5 billion by 2028, exhibiting a CAGR of 4.5% during the forecast period (2022-2028). The market is driven by the increasing prevalence of mental health disorders, such as schizophrenia, bipolar disorder, and major depressive disorder. Recent developments include: The Aripiprazole Market has seen significant developments recently, with several pharmaceutical companies involved in strategic initiatives. Torrent Pharmaceuticals has been expanding its portfolio, focusing on enhancing production capacity for Aripiprazole formulations to meet growing demand. Sun Pharmaceutical is also making strides by investing in research to improve drug formulations and efficacy. Underlining the competitive landscape, Lupin Pharmaceuticals has been leveraging mergers to strengthen its market presence, while Intas Pharmaceuticals is collaborating with healthcare professionals for better patient outcomes. Notably, growth in market valuation is evident as companies like Cipla and Par Pharmaceutical report increased sales driven by heightened demand. Furthermore, Teva Pharmaceutical and Hikma Pharmaceuticals are engaging in strategic partnerships to boost the distribution of Aripiprazole globally. The recent acquisition activities and expansions by Mylan and Aurobindo Pharma reflect a shift towards consolidating market positions. Lastly, Dr. Reddy's Laboratories and Otsuka Pharmaceutical continue to innovate, with new studies aimed at enhancing therapeutic applications of Aripiprazole. Overall, these advancements denote a dynamic and evolving environment in the Aripiprazole Market.. Key drivers for this market are: Growing prevalence of mental disorders, Expanding generic formulations availability; Advancements in drug delivery systems; Rising demand in emerging markets; Increasing mental health awareness campaigns. Potential restraints include: Increasing schizophrenia diagnoses, Growing generic drug availability; Rising mental health awareness; Expanding treatment options; Stringent regulatory approvals.

$ Only sociodemographic variables used in post-stratification of weight are presented.* Weighted Percentages calculated using part 1 weights** Weighted Percentages calculated using part 2 weights# Centro Regional de Estadística de Murcia; Padrón 2010# Completed years of education (four categories: None or primary: 0–7 years; Basic: 8–11 years; Secondary: 12–15 years and College: 16 or more years of education).Sociodemographic distribution of the PEGASUS-Murcia sample compared to general population$.

This statistic displays the age-standardized suicide rate in Canada from 1950 to 2009. In 1950, the suicide rate in the country reached 9.1 per 100,000 population for both sexes. Many people who have committed suicide have some form of depression, a serious mood disorder that can impact one's occupation, social life, education, and other parts of their lives.

Age-group specific changes in age-adjusted mortality rates for four suicide methods (annual percentage change > = 1) in males and females between 2007 and 2010 in Germany. (DOC)

During 2021, the number of suicides in Canada reached 312 among people between the ages of 40 and 44. Many people who have committed suicide have some form of depression, a serious mood disorder that can impact one's occupation, social life, education, and other parts of their lives. This statistic displays the number of suicides in Canada in 2021, by age group.